The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Shop Purgo Labs

Retatrutide vs Semaglutide

Retatrutide vs Semaglutide: triple agonist vs pure GLP-1 agonist. Phase 3 data shows retatrutide produces 24.2% weight loss vs 14.9% for semaglutide — approximately 60% more weight loss.

Clinical Trial Comparison

Semaglutide (STEP-1): 14.9% weight loss at 68 weeks. Retatrutide (TRIUMPH-1): 24.2% at 48 weeks. The difference of approximately 9 percentage points represents roughly 60% more weight loss for a typical research subject.

Mechanism Difference

Semaglutide: GLP-1 receptor agonism only. Retatrutide: GLP-1 + GIP + glucagon triple agonism. The glucagon component increases energy expenditure and hepatic fat reduction — the primary driver of retatrutide's superior weight loss.

Regulatory Consideration

Semaglutide is FDA-approved; retatrutide is in Phase 3 trials as of 2026. For any protocol requiring an approved compound, semaglutide (Ozempic/Wegovy) is the appropriate choice.